UK markets close in 3 hours 53 minutes
  • FTSE 100

    +86.54 (+1.20%)
  • FTSE 250

    +317.64 (+1.39%)
  • AIM

    +13.19 (+1.12%)

    +0.0015 (+0.13%)

    -0.0018 (-0.13%)

    +1,309.73 (+3.54%)
  • CMC Crypto 200

    +49.34 (+3.92%)
  • S&P 500

    +53.24 (+1.17%)
  • DOW

    +646.95 (+1.87%)

    +2.14 (+3.08%)

    +5.10 (+0.29%)
  • NIKKEI 225

    +528.23 (+1.89%)

    +634.28 (+2.72%)
  • DAX

    +321.05 (+2.09%)
  • CAC 40

    +160.56 (+2.34%)

TAE Life Sciences to Sponsor Industry Expert Theater "New Era in Biologically-Targeted Radiation Therapy" at 2021 ASTRO Annual Meeting

·3-min read

Mayo Clinic, National Center of Oncological Hadrontherapy in Italy (CNAO) and TAE Life Sciences to discuss advancements in boron neutron capture therapy for treatment of cancer

FOOTHILL RANCH, Calif., October 18, 2021--(BUSINESS WIRE)--TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the sponsorship of an Industry-Expert Theater session focused on advancements in BNCT at the American Society for Radiation Oncology (ASTRO) Annual Meeting, occurring October 24-27, 2021.

The session, "New Era in Biologically-Targeted Radiation Therapy: Clinical Application and Technical Advancement in Boron Neutron Capture Therapy" will feature presentations by Timothy Malouff, M.D., Mayo Clinic, Ester Orlandi, M.D., National Center of Oncological Hadrontherapy (CNAO) and Kendall Morrison, Ph.D., Chief Scientific Officer, TAE Life Sciences. They will discuss the clinical application and technical advancements in BNCT for the treatment of invasive, recurrent and difficult to treat cancers.

"Our deep commitment to innovation in clinical practice is underscored by our research in BNCT as an emerging treatment modality for traditionally difficult to treat tumors," said Dr. Timothy Malouff, Mayo Clinic. "With clinical studies in a variety of disease sites including head and neck cancers, lung cancers, and breast cancers, BNCT holds the promise of transforming the cancer treatment landscape. We look forward to sharing an update on the current clinical research at ASTRO."

"We announced a partnership with TAE Life Sciences last year to provide BNCT for the treatment of invasive, recurrent and difficult to treat cancers," said Dr. Ester Orlandi, Medical Director at CNAO. "Taking part in this session enables us to provide an update on how we are providing a new pillar in cancer therapy."

Session Title: New Era in Biologically-Targeted Radiation Therapy: Clinical Application and Technical Advancement in Boron Neutron Capture Therapy
Location: Theater 1, Innovation Hub, McCormick Place West
Date: Monday, Oct 25 2:45 PM

About BNCT

BNCT is a combination treatment based on the reaction that occurs when a non-toxic compound containing boron-10 is irradiated with a low-energy neutron beam. BNCT differs radically from other radiation therapy and shows promise in becoming the next-generation cancer treatment. Research has shown BNCT has the capability of killing cancer cells that are resistant to traditional radiation therapy with limited harm to healthy tissue. Current advances in both neutron radiation technology and medicinal boron drug targeting are enabling BNCT’s potential to improve patient care while also improving treatment economics. To date, approximately 2,000 patients have been treated with BNCT at research sites worldwide.

About TAE Life Sciences

TAE Life Sciences (TLS) is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TLS is developing the next generation targeted boron drugs and low-energy accelerator-based neutron source – optimized for an in-hospital BNCT program that can one day treat patients with the most aggressive and recurrent cancers. We have assembled a world-class, cross-functional team of clinicians, radiation oncologists, physicists, and other researchers to enable us to bring our technology to cancer patients who need it most. TLS’s target drugs and neutron radiation system are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at

View source version on


Lauren Arnold

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting